Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy].

Pathologie-biologie - 1 Jul 2007

Siguret V

Abstract excerpt

Vitamin K antagonists (VKA) are difficult to use because of a narrow therapeutic index and of a marked inter- and intra individual variability among patients in the required dosage. Beside well known demographic or environmental factors (advanced age, co-morbid conditions, acute illnesses, concomitant drugs, vitamin K intake), genetic single nucleotide polymorphisms (SNPs) have been identified as strongly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Variation

Share to Mixed Function Oxygenases

Share to Polymorphism, Single Nucleotide

Share to Vitamin K

Share to Vitamin K Epoxide Reductases

Source

Identifiers

PMID: 17611042
DOI: 10.1016/j.patbio.2007.04.001

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy].PMID 17611042Read ↗

Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin.Semantic proximity Read ↗

[The pharmacogenetics of vitamin K antagonists: still a matter for discussion].Semantic proximity Read ↗

[Oral anticoagulation and pharmacogenetics: importance in the clinical setting].Semantic proximity Read ↗

[Pharmacogenomics of vitamin K antagonists].Semantic proximity Read ↗

Pharmacogenetics aspects of oral anticoagulants therapy.Semantic proximity Read ↗

Investigating warfarin variability : the contribution of clinical, genetic, and environmental factorsSemantic proximity Read ↗

Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study.Semantic proximity Read ↗

Warfarin and vitamin K intake in the era of pharmacogenetics.Semantic proximity Read ↗

[Genetic determinants of response to vitamin K antagonists].Semantic proximity Read ↗

Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.Semantic proximity Read ↗

Contribution of CYP2C9 to variability in vitamin K antagonist metabolism.Semantic proximity Read ↗

Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.